Pub Date : 2026-02-06DOI: 10.1007/s12072-026-11036-0
Sohana Memon, Gaaitri Lohano, Govinda Lohano
{"title":"Letter to the Editor: \"Critical appraisal of MASLD subtypes and pregnancy outcome associations in a nationwide cohort\".","authors":"Sohana Memon, Gaaitri Lohano, Govinda Lohano","doi":"10.1007/s12072-026-11036-0","DOIUrl":"https://doi.org/10.1007/s12072-026-11036-0","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-05DOI: 10.1007/s12072-026-11033-3
Young Mi Jung, Geum Joon Cho, Won Kim
{"title":"Response to letter to editor: toward more precise and generalizable evidence on MASLD and pregnancy risks.","authors":"Young Mi Jung, Geum Joon Cho, Won Kim","doi":"10.1007/s12072-026-11033-3","DOIUrl":"https://doi.org/10.1007/s12072-026-11033-3","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-05DOI: 10.1007/s12072-026-11047-x
Yun Kyung Cho, Chang Hee Jung
{"title":"Response to letter to the editor \"Diagnostic criteria for fatty liver disease: lessons from other diseases\".","authors":"Yun Kyung Cho, Chang Hee Jung","doi":"10.1007/s12072-026-11047-x","DOIUrl":"https://doi.org/10.1007/s12072-026-11047-x","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-05DOI: 10.1007/s12072-026-11051-1
Sitong Chen, Yuejuan Gao, GuangWen Cheng, FanKun Meng, Ying Zheng, Bo Zhang, Jie Chen, Yao Zhang, Zhiyong Yin, Hong Yang, Peng Lin, ShuJing Wei, Xiting Xu, Bulin Zhang, Wei Zhang, Lixin Yang, Yadan Tang, Xueling Liu, Dan Wang, Hong Ding, Ping Liang, Jie Yu
Background: The binary diagnostic approach does not reflect the entire spectrum of metabolic dysfunction associated steatotic liver disease (MASLD. We used an elastography technology, dual elastography ultrasound (DEUS), to discriminate the different stages of MASLD.
Method: This prospective multicenter study was conducted from December 2020 to March 2022. All patients underwent DEUS scan, a liver biopsy, and a liver function laboratory test. The optimal model was developed (ModelDEUSC) with 10 machine learning algorithms by combining DEUS and selected clinical parameters and tested the diagnostic accuracy for distinguishing the three progression stages of MASLD: low-, intermediate-, and high-risk. The diagnostic ability of ModelDEUSC for MASH with advanced fibrosis (≥ F3) was compared with other four non-invasive tests.
Results: The study included 312 patients in the derivation cohort and 135 in the validation cohort (7:3). Combining DEUS and clinical parameters, a ternary classification of MASLD in the validation cohort achieved a macro-average AUC of 0.858 (95% CI: 0.793, 0.925). The AUC for the diagnosis of MASH with ≥ F3 fibrosis of ModelDEUSC was 0.886 (95% CI: 0.813, 0.824), which was superior to FAST, FIB-4, NFS, and APRI (0.822, 0.657, 0.688, and 0.659). Moreover, ModelDEUSC demonstrated favorable performance for distinguishing stages of liver fibrosis (F1 to F4), inflammation (G1 to G4), and steatosis (S1 to S4). Stratification analysis showed that the ability of ModelDEUSC was not influenced by diabetes and obesity.
Conclusion: Multicenter data analysis demonstrated DEUS' advanced ability in continuous stratification of MASLD, which will provide a low-cost, easily accessible, and accurate noninvasive tools (NIT) for MASLD.
{"title":"Dual elastography ultrasound for classifying metabolic dysfunction-associated steatotic liver disease: a cross-sectional study within a prospective cohort.","authors":"Sitong Chen, Yuejuan Gao, GuangWen Cheng, FanKun Meng, Ying Zheng, Bo Zhang, Jie Chen, Yao Zhang, Zhiyong Yin, Hong Yang, Peng Lin, ShuJing Wei, Xiting Xu, Bulin Zhang, Wei Zhang, Lixin Yang, Yadan Tang, Xueling Liu, Dan Wang, Hong Ding, Ping Liang, Jie Yu","doi":"10.1007/s12072-026-11051-1","DOIUrl":"https://doi.org/10.1007/s12072-026-11051-1","url":null,"abstract":"<p><strong>Background: </strong>The binary diagnostic approach does not reflect the entire spectrum of metabolic dysfunction associated steatotic liver disease (MASLD. We used an elastography technology, dual elastography ultrasound (DEUS), to discriminate the different stages of MASLD.</p><p><strong>Method: </strong>This prospective multicenter study was conducted from December 2020 to March 2022. All patients underwent DEUS scan, a liver biopsy, and a liver function laboratory test. The optimal model was developed (Model<sup>DEUSC</sup>) with 10 machine learning algorithms by combining DEUS and selected clinical parameters and tested the diagnostic accuracy for distinguishing the three progression stages of MASLD: low-, intermediate-, and high-risk. The diagnostic ability of Model<sup>DEUSC</sup> for MASH with advanced fibrosis (≥ F3) was compared with other four non-invasive tests.</p><p><strong>Results: </strong>The study included 312 patients in the derivation cohort and 135 in the validation cohort (7:3). Combining DEUS and clinical parameters, a ternary classification of MASLD in the validation cohort achieved a macro-average AUC of 0.858 (95% CI: 0.793, 0.925). The AUC for the diagnosis of MASH with ≥ F3 fibrosis of Model<sup>DEUSC</sup> was 0.886 (95% CI: 0.813, 0.824), which was superior to FAST, FIB-4, NFS, and APRI (0.822, 0.657, 0.688, and 0.659). Moreover, Model<sup>DEUSC</sup> demonstrated favorable performance for distinguishing stages of liver fibrosis (F1 to F4), inflammation (G1 to G4), and steatosis (S1 to S4). Stratification analysis showed that the ability of Model<sup>DEUSC</sup> was not influenced by diabetes and obesity.</p><p><strong>Conclusion: </strong>Multicenter data analysis demonstrated DEUS' advanced ability in continuous stratification of MASLD, which will provide a low-cost, easily accessible, and accurate noninvasive tools (NIT) for MASLD.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-05DOI: 10.1007/s12072-026-11037-z
Yasuto Takeuchi, Ryosuke Tateishi, Shuntaro Obi, Motoyuki Otsuka, Hitoshi Mochizuki, Amarsanaa Jazag, Osamu Yokosuka, Sadahisa Ogasawara, Naoya Kanogawa, Erdenebayar Gonchig, Yuki Matsushita, Murat Kekilli, Gulden Bilican, Yoon Jun Kim, Moon Haeng Hur, Ming-Lung Yu, Chung-Feng Huang, Asahiro Morishita, Kyoko Oura, Atsumasa Komori, Yasuhide Motoyoshi, Lianda Siregar, Imelda Loho, Ming Yang, Shuichirou Okabe, Yoshiyuki Ueno, Tomohiro Katsumi, Takahisa Sato, Hirofumi Kogure, Ryota Masuzaki, Cosmas Rinaldi Lesmana, S H H Nababan, Supot Nimanong, Yi-Hsiang Huang, Hiroaki Nagamatsu, Hideo Yoshida, Koji Uchino, Irsan Hasan, Taya Kitiyakara, Masatoshi Akamatsu, Makoto Okamoto, Mayuko Kondo, Makoto Moriyama, Wattana Sukeepaisarnjareon, Pisit Tangkijvanich, Kessarin Thanapirom, Kendal Yalcin, Hayriye Dilan Kızıl, Gupse Adali, Meral Akdogan, Dilara Turan Gokce, Yasemin Balaban, Hale Gokcan, Arif Mansur Coşar, Murat Harputluoglu, İbrahim Halil Bahçecioğlu, Alp Atasoy, Muhammet Cem Kockar, Hakan Dursun, Ahmet Tarik Eminler, Jose Sollano, Dong Jin Su, Teerha Piratvisuth, Jia-Horng Kao, Darrell Crawford, Jinlin Hou, Barjesh Chander Sharma, Diana Alcantara Payawal, Rino Alvani Gani, Tawesak Tanwandee, Jin Mo Yang, Han-Chieh Lin, Shuichiro Shiina, Ji-Dong Jia, George Lau, Necati Örmeci, A Kadir Dokmeci, Lai Wei, Shiv Kumar Sarin, Masao Omata
Background: Hepatocellular carcinoma (HCC) remains a major health burden in Asia. Advances in antiviral therapies are reshaping the etiological landscape of HCC. This study evaluated temporal shifts in HCC etiology across Asian countries and their clinical implications.
Methods: This multinational study analyzed 6,261 newly diagnosed HCC patients registered in the APASL Hepatology/Oncology Consortium (A-HOC) from 19 centers across seven Asian countries and regions between 2013 and 2023. Data on demographics, tumor characteristics, etiology, and treatment patterns were collected. Etiologies included hepatitis B virus (HBV), hepatitis C virus (HCV), alcoholic liver disease (ALD), metabolic dysfunction-associated fatty liver disease (MAFLD), MAFLD plus excess alcoholic intake (MAFLD + eAL), autoimmune liver disease, cryptogenic, and others. Temporal trends and regional variations were assessed.
Results: In many countries, HBV remained predominant (43.3%-69.5%) and relatively stable throughout the period, while HCV showed only modest reductions. In Japan, HCV was the leading cause of HCC (33.1%), with a significant decline over time, accompanied by a rise in MAFLD-related HCC. ALD-related HCC increased in South Korea, and MAFLD-related HCC rose in Turkey. Tumor size and stage at diagnosis varied by etiology and region, affecting treatment strategies. Early-stage diagnosis was more frequent in Japan and Taiwan, whereas advanced-stage HCC was common in China and Indonesia.
Conclusions: Distinct regional patterns and temporal changes in HCC etiology across Asia highlight the need for tailored prevention and surveillance measures. The growing burden of MAFLD-related HCC emphasizes its emerging role in liver cancer development, particularly in regions with declining viral hepatitis.
{"title":"Temporal trends and regional variations in hepatocellular carcinoma etiology: a multinational study across Asia.","authors":"Yasuto Takeuchi, Ryosuke Tateishi, Shuntaro Obi, Motoyuki Otsuka, Hitoshi Mochizuki, Amarsanaa Jazag, Osamu Yokosuka, Sadahisa Ogasawara, Naoya Kanogawa, Erdenebayar Gonchig, Yuki Matsushita, Murat Kekilli, Gulden Bilican, Yoon Jun Kim, Moon Haeng Hur, Ming-Lung Yu, Chung-Feng Huang, Asahiro Morishita, Kyoko Oura, Atsumasa Komori, Yasuhide Motoyoshi, Lianda Siregar, Imelda Loho, Ming Yang, Shuichirou Okabe, Yoshiyuki Ueno, Tomohiro Katsumi, Takahisa Sato, Hirofumi Kogure, Ryota Masuzaki, Cosmas Rinaldi Lesmana, S H H Nababan, Supot Nimanong, Yi-Hsiang Huang, Hiroaki Nagamatsu, Hideo Yoshida, Koji Uchino, Irsan Hasan, Taya Kitiyakara, Masatoshi Akamatsu, Makoto Okamoto, Mayuko Kondo, Makoto Moriyama, Wattana Sukeepaisarnjareon, Pisit Tangkijvanich, Kessarin Thanapirom, Kendal Yalcin, Hayriye Dilan Kızıl, Gupse Adali, Meral Akdogan, Dilara Turan Gokce, Yasemin Balaban, Hale Gokcan, Arif Mansur Coşar, Murat Harputluoglu, İbrahim Halil Bahçecioğlu, Alp Atasoy, Muhammet Cem Kockar, Hakan Dursun, Ahmet Tarik Eminler, Jose Sollano, Dong Jin Su, Teerha Piratvisuth, Jia-Horng Kao, Darrell Crawford, Jinlin Hou, Barjesh Chander Sharma, Diana Alcantara Payawal, Rino Alvani Gani, Tawesak Tanwandee, Jin Mo Yang, Han-Chieh Lin, Shuichiro Shiina, Ji-Dong Jia, George Lau, Necati Örmeci, A Kadir Dokmeci, Lai Wei, Shiv Kumar Sarin, Masao Omata","doi":"10.1007/s12072-026-11037-z","DOIUrl":"https://doi.org/10.1007/s12072-026-11037-z","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) remains a major health burden in Asia. Advances in antiviral therapies are reshaping the etiological landscape of HCC. This study evaluated temporal shifts in HCC etiology across Asian countries and their clinical implications.</p><p><strong>Methods: </strong>This multinational study analyzed 6,261 newly diagnosed HCC patients registered in the APASL Hepatology/Oncology Consortium (A-HOC) from 19 centers across seven Asian countries and regions between 2013 and 2023. Data on demographics, tumor characteristics, etiology, and treatment patterns were collected. Etiologies included hepatitis B virus (HBV), hepatitis C virus (HCV), alcoholic liver disease (ALD), metabolic dysfunction-associated fatty liver disease (MAFLD), MAFLD plus excess alcoholic intake (MAFLD + eAL), autoimmune liver disease, cryptogenic, and others. Temporal trends and regional variations were assessed.</p><p><strong>Results: </strong>In many countries, HBV remained predominant (43.3%-69.5%) and relatively stable throughout the period, while HCV showed only modest reductions. In Japan, HCV was the leading cause of HCC (33.1%), with a significant decline over time, accompanied by a rise in MAFLD-related HCC. ALD-related HCC increased in South Korea, and MAFLD-related HCC rose in Turkey. Tumor size and stage at diagnosis varied by etiology and region, affecting treatment strategies. Early-stage diagnosis was more frequent in Japan and Taiwan, whereas advanced-stage HCC was common in China and Indonesia.</p><p><strong>Conclusions: </strong>Distinct regional patterns and temporal changes in HCC etiology across Asia highlight the need for tailored prevention and surveillance measures. The growing burden of MAFLD-related HCC emphasizes its emerging role in liver cancer development, particularly in regions with declining viral hepatitis.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-04DOI: 10.1007/s12072-026-11046-y
Young Mi Jung, Geum Joon Cho, Won Kim
{"title":"Response to Letter to Editor: Revisiting MASLD-based pregnancy risk stratification.","authors":"Young Mi Jung, Geum Joon Cho, Won Kim","doi":"10.1007/s12072-026-11046-y","DOIUrl":"https://doi.org/10.1007/s12072-026-11046-y","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-04DOI: 10.1007/s12072-026-11045-z
Yan Zhang
{"title":"Regarding the methodological aspects of the TabPFN model for predicting post-TIPS hepatic encephalopathy.","authors":"Yan Zhang","doi":"10.1007/s12072-026-11045-z","DOIUrl":"https://doi.org/10.1007/s12072-026-11045-z","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号